The company's VISTA platform is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. InterVenn's GlycoVision™ platform, powered by artificial intelligence (AI) and advanced machine learning (ML), can achieve in minutes what would take a human operator months to achieve. InterVenn aims to provide healthcare professionals with the power to work ahead of the onset of disease, and in 2023, they will launch GlycoKnow™ Colon, a laboratory-developed test that uses glycoproteomics to pinpoint precursors to colon cancer with a single blood draw.